Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,501.24
(
0.77%
)
US TECH 100
28,788.80
(
0.70%
)
Dow Jones
50,063.46
(
0.75%
)
Brent Oil
105.09
(
0.87%
)
Bitcoin
80,435.32
(
-0.77%
)
News Focus
News Focus
Post# of 257566
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122982
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 63998

Thursday, 07/24/2008 12:33:56 PM

Thursday, July 24, 2008 12:33:56 PM

Post# of 257566
NUVO NU172 notes from 2Q08 CC:

CEO Ted Love said NU172 has several benefits vs other anticoagulants for the CABG and dialysis settings: ability to act in stagnant blood, rapid on/off without an antidote, and lack of renal clearance (especially important in dialysis setting).

NU172 is in phase-1b (#msg-29771841).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today